All Biopharma Haig looking back

Getting drug pricing right – Manufacturing Chemist

In late 2017, we wrote an article on successful drug pricing. In light of COVID 19, we’re republishing this article “Pharmaceutical companies view Covid-19 as a once-in-a-lifetime business opportunity,” said Gerald Posner, author of “Pharma: Greed, Lies, and the Poisoning of America.” In the US, coronavirus vaccine funding has been given by the US Gov to organisations to aid vaccine development but there’s concern that an exclusive licence will be issued to a pharmaceutical company with no conditions on pricing. This would give the licensee the ability to sell it back to the public, who paid for its development, at a vast profit. Will pharmaceutical companies learn from EpiPen, Daraprim and other pricing mistakes which caused public outrage? Or will they take a more sustainable, optimised pricing model with a view to benefiting all in the value chain? We at Haig Barrett will be watching this unprecedented situation and will endeavour to keep you updated with our commentary as events unfold.

Getting Drug Pricing Right, Manufacturng Chemist - NOV 2017
Getting Drug Pricing Right, Manufacturng Chemist - NOV 2017 2
Getting Drug Pricing Right, Manufacturng Chemist - NOV 2017 3